| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/21/2013 | US20130045982 Benzamide derivatives |
| 02/21/2013 | US20130045980 Imidazopyridazinyl compounds |
| 02/21/2013 | US20130045977 TGF-beta SIGNAL TRANSDUCTION INHIBITOR |
| 02/21/2013 | US20130045976 Isoindoline compounds and methods of their use |
| 02/21/2013 | US20130045963 Cyclohexyl Azetidine Derivatives as JAK Inhibitors |
| 02/21/2013 | US20130045956 Preventive and/or therapeutic agent of hand-foot syndrome |
| 02/21/2013 | US20130045955 Novel compounds |
| 02/21/2013 | US20130045951 Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof |
| 02/21/2013 | US20130045950 Phosphonate Compounds |
| 02/21/2013 | US20130045949 Anti-cancer agents |
| 02/21/2013 | US20130045947 Pla2activity as a marker for ovarian and other gynecologic cancers |
| 02/21/2013 | US20130045946 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved |
| 02/21/2013 | US20130045944 Anti-Cancer Therapies |
| 02/21/2013 | US20130045938 Kinase modulators for the treatment of cancer |
| 02/21/2013 | US20130045935 Flavonoid dimers and their use |
| 02/21/2013 | US20130045934 Extraction method using ultra fine bubbles and liquid extracts obtained thereof |
| 02/21/2013 | US20130045933 Aloe-emodin derivatives and use thereof for the treatment of cancer |
| 02/21/2013 | US20130045931 Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes |
| 02/21/2013 | US20130045925 Compositions for ameliorating cell proliferative disorders and methods of making and using them |
| 02/21/2013 | US20130045520 Double-stranded oligonucleotides |
| 02/21/2013 | US20130045288 Method for Treating Prostate Cancer |
| 02/21/2013 | US20130045286 Pyrrolopyridines as kinase inhibitors |
| 02/21/2013 | US20130045272 Agent for treating myelofibrosis |
| 02/21/2013 | US20130045244 Modified adam disintegrin domain polypeptides and uses thereof |
| 02/21/2013 | US20130045243 NANOGENOMICS FOR MEDICINE: siRNA ENGINEERING |
| 02/21/2013 | US20130045240 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 02/21/2013 | US20130045236 Diagnostic and therapeutic uses of soluble fc-epsilon receptor i for ige-mediated disorders |
| 02/21/2013 | US20130045235 Autologous biological cancer vaccine |
| 02/21/2013 | US20130045234 Neutralizing factors as vaccine adjuvants |
| 02/21/2013 | US20130045220 Microvesicle Membrane Protein And Application Thereof |
| 02/21/2013 | US20130045214 P53 modulator and cancer target |
| 02/21/2013 | US20130045210 Pharmaceutical composition for treating and/or preventing cancer |
| 02/21/2013 | US20130045209 WNT-Binding Agents and Uses Thereof |
| 02/21/2013 | US20130045206 Antibodies directed against the transferrin receptor and uses thereof for immunotherapy of iron-dependent tumours |
| 02/21/2013 | US20130045204 Fluorinated bisphenol ether compounds and methods for their use |
| 02/21/2013 | US20130045203 Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
| 02/21/2013 | US20130045202 Anti-pd-l1 antibodies and articles of manufacture |
| 02/21/2013 | US20130045201 Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity |
| 02/21/2013 | US20130045191 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 02/21/2013 | US20130045188 Reduction of tgf beta signaling in myeloid cells in the treatment of cancer |
| 02/21/2013 | US20130045180 Vaccines, immunotherapeutics and methods for using the same |
| 02/21/2013 | US20130045179 Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
| 02/21/2013 | US20130045165 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators |
| 02/21/2013 | US20130045163 Treatment of metastatic tumors |
| 02/21/2013 | US20130045162 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | CA2845583A1 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 02/21/2013 | CA2845536A1 Anti-b7-h4 antibodies and their uses |
| 02/21/2013 | CA2845030A1 Piperazine derivatives |
| 02/21/2013 | CA2844985A1 Tricyclic compounds as anticancer agents |
| 02/21/2013 | CA2844982A1 Lysophosphatidic acid receptor antagonists |
| 02/21/2013 | CA2844930A1 Compositions and methods for inducing apoptosis |
| 02/21/2013 | CA2844794A1 Heterocyclic derivative and pharmaceutical |
| 02/21/2013 | CA2844783A1 Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer |
| 02/21/2013 | CA2844674A1 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
| 02/21/2013 | CA2844500A1 Yeast-muc1 immunotherapeutic compositions and uses thereof |
| 02/21/2013 | CA2844289A1 Anti-fzd10 monoclonal antibodies and methods for their use |
| 02/21/2013 | CA2842887A1 Mphosph1 peptides and vaccines including the same |
| 02/21/2013 | CA2842481A1 Inhibition of angiogenesis in refractory tumors |
| 02/21/2013 | CA2842375A1 Neuregulin antibodies and uses thereof |
| 02/21/2013 | CA2839647A1 Folate conjugates of albumin-binding entities |
| 02/21/2013 | CA2838784A1 Pyrazolo[3,4-c]pyridine compounds and methods of use |
| 02/20/2013 | EP2559762A1 Novel anti-hsp90 monoclonal antibody |
| 02/20/2013 | EP2559706A1 Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
| 02/20/2013 | EP2559705A2 Anti-activin a antibodies and uses thereof |
| 02/20/2013 | EP2559690A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| 02/20/2013 | EP2559686A1 Therapeutic quinoline and naphthalene derivatives |
| 02/20/2013 | EP2559441A2 Protein complex for intracellular delivery and uses thereof |
| 02/20/2013 | EP2559429A2 Anticancer drug delivery system using ph-sensitive metal nanoparticles |
| 02/20/2013 | EP2558866A1 Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| 02/20/2013 | EP2558498A2 Antibodies that bind human cd27 and uses thereof |
| 02/20/2013 | EP2558475A1 Pyrrolobenzodiazepines used to treat proliferative diseases |
| 02/20/2013 | EP2558469A1 Pyrrolopyrazinone inhibitors of kinases |
| 02/20/2013 | EP2558459A1 Phthalazin-(2h)-one inhibitors of kinases |
| 02/20/2013 | EP2558454A2 Androgen induced oxidative stress inhibitors |
| 02/20/2013 | EP2558452A2 Oxazole and thiazole compounds as ksp inhibitors |
| 02/20/2013 | EP2558450A1 Triazole compounds as ksp inhibitors |
| 02/20/2013 | EP2558127A1 Targeted pyrrolobenzodiazapine conjugates |
| 02/20/2013 | EP2558125A2 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity |
| 02/20/2013 | EP2558124A1 Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| 02/20/2013 | EP2558123A2 Methods and compositions for inhibition of treg cells |
| 02/20/2013 | EP2558122A1 Combination treatment with vegf-c antagonists |
| 02/20/2013 | EP2558109A2 Method for treating solid tumors |
| 02/20/2013 | EP2558098A2 Treatment of endocrine resistant breast cancer |
| 02/20/2013 | EP2558096A1 Combination of hypoxia-inducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors |
| 02/20/2013 | EP2558095A1 Organic compound for use in the treatment of liver cancer |
| 02/20/2013 | EP2558092A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| 02/20/2013 | EP2558090A1 Radiation sensitiser compositions |
| 02/20/2013 | EP2558086A1 Homeopathic medicament comprising phenacetin for the treatment of cancer |
| 02/20/2013 | EP2558085A2 Compositions and methods for the prevention and treatment of cancer |
| 02/20/2013 | EP2558083A1 Methods for providing enhanced resveratrol activity using 4-acetoxy-resveratrol |
| 02/20/2013 | EP2558082A1 Combination of organic compounds |
| 02/20/2013 | EP2557923A1 Treatment of cancers having k-ras mutations |
| 02/20/2013 | CN102939305A Antibodies to cd122 |
| 02/20/2013 | CN102939300A Preparation of crystalline ezatiostat hydrochloride ansolvate form d |
| 02/20/2013 | CN102939292A Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 02/20/2013 | CN102939287A 雌激素受体调节剂及其用途 Estrogen receptor modulators and their use |
| 02/20/2013 | CN102939286A Polysubstituted benzofurans and medicinal applications thereof |
| 02/20/2013 | CN102939109A Combination of drugs with protein-binding prodrugs |
| 02/20/2013 | CN102939087A Novel indazole derivative or salt thereof, manufacturing intermediate therefor, antioxidant using same, and use for an indazole derivative or salt thereof |
| 02/20/2013 | CN102939086A Method of treating gastric cancer |